A Multicenter, Single-Arm, Open-Label, Phase 2 Study of Apitolisib (GDC-0980) for the Treatment of Recurrent or Persistent Endometrial Carcinoma (MAGGIE study)

BACKGROUND: This single arm, open-label trial was designed to evaluate the activity of apitolisib (GDC-0980), a dual PI3K/mTOR inhibitor, in patients with advanced endometrial cancer (EC). METHODS: Patients with recurrent or persistent EC treated with 1–2 prior lines of chemotherapy but no prior PI3...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer
Hauptverfasser: Makker, Vicky, Recio, Fernando O., Ma, Ling, Matulonis, Ursula, Lauchle, Jennifer O., Parmar, Hema, Gilbert, Houston N., Ware, Joseph A., Zhu, Rui, Lu, Shan, Huw, Ling-Yuh, Wang, Yulei, Koeppen, Hartmut, Spoerke, Jill M., Lackner, Mark R., Aghajanian, Carol
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2016
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5600677/
https://ncbi.nlm.nih.gov/pubmed/27603005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30286
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge